EGFR and neoplasm: This study aimed to describe the clinical characteristics and outcomes of mCRC patients with RAS WT left-sided tumours treated with first-line chemotherapy in combination with EGFR inhibitors, chemotherapy in combination with bevacizumab, or chemotherapy alone in Alberta, Canada, using population-based data.